Non‐transfusion‐dependent thalassaemias (NTDT) comprise a heterogeneous group of anaemias characterised by impaired production of β‐globin and/or α‐globin chains, for which ineffective erythropoiesis is the underlying mechanism for anaemia (Vichinsky, [2007](#bjh14373-bib-0039){ref-type="ref"}; Fucharoen & Viprakasit, [2009](#bjh14373-bib-0006){ref-type="ref"}; Galanello & Origa, [2010](#bjh14373-bib-0008){ref-type="ref"}; Harteveld & Higgs, [2010](#bjh14373-bib-0011){ref-type="ref"}). Three main diagnostic subgroups have been identified: β thalassaemia intermedia (β TI), haemoglobin (Hb) E/β thalassaemia and Hb H syndromes (Weatherall, [2012](#bjh14373-bib-0042){ref-type="ref"}). Management strategies are highly diverse, and may include close observation, sporadic transfusion, splenectomy and Hb F‐inducing agents (Taher *et al*, [2011](#bjh14373-bib-0034){ref-type="ref"}; Fucharoen & Weatherall, [2012](#bjh14373-bib-0007){ref-type="ref"}; Musallam *et al*, [2012](#bjh14373-bib-0017){ref-type="ref"}; Vichinsky, [2013](#bjh14373-bib-0040){ref-type="ref"}).

Patients with NTDT, as well as other iron‐loading anaemias, become iron overloaded mainly because of increased iron absorption (Pippard *et al*, [1979](#bjh14373-bib-0024){ref-type="ref"}; Pootrakul *et al*, [1988](#bjh14373-bib-0025){ref-type="ref"}), which averages 0·011 mg/kg/day in the absence of transfusion therapy (Taher *et al*, [2012](#bjh14373-bib-0035){ref-type="ref"}); sporadic transfusions also directly contribute to further iron accumulation. However, the parameters accounting for variability in iron absorption across the range of NTDT diagnostic subgroups are not well described (Table SI). In principle, iron accumulation could be increased in line with the degree of anaemia and/or by erythroid expansion, both driving down synthesis of the iron regulatory protein hepcidin and hence increasing dietary iron absorption. Bone‐marrow‐derived factors associated with ineffective erythropoiesis have been implicated in inhibiting hepcidin synthesis, including growth differentiation factor 15 (GDF‐15) in humans (Tanno *et al*, [2007](#bjh14373-bib-0038){ref-type="ref"}; Tanno & Miller, [2010](#bjh14373-bib-0037){ref-type="ref"}) and, more recently, erythroferrone in mice (Kautz *et al*, [2014](#bjh14373-bib-0012){ref-type="ref"}). In addition, GDF‐11 has recently been identified as a key factor associated with ineffective erythropoiesis in a mouse model of thalassaemia (Dussiot *et al*, [2014](#bjh14373-bib-0004){ref-type="ref"}). The same mechanism will also increase the release of recycled iron from the reticuloendothelial system, thus depleting macrophage iron. This typically explains the preferential periportal and hepatocyte iron loading with increased liver iron concentration (LIC) (Origa *et al*, [2007](#bjh14373-bib-0021){ref-type="ref"}; Taher *et al*, [2009a](#bjh14373-bib-0032){ref-type="ref"}, [2011](#bjh14373-bib-0034){ref-type="ref"}; Gardenghi *et al*, [2010](#bjh14373-bib-0010){ref-type="ref"}; Tanno & Miller, [2010](#bjh14373-bib-0037){ref-type="ref"}). Chronic anaemia and hypoxia also induce expression of hypoxia‐inducible transcription factors (Tanno & Miller, [2010](#bjh14373-bib-0037){ref-type="ref"}) and stimulate erythropoietin (EPO) synthesis, thus inducing erythropoiesis and erythron expansion, which further augments iron absorption.

The THALASSA (Assessment of Exjade in Non‐Transfusion‐Dependent Thalassaemia) trial was a prospective, randomised, double‐blind, placebo‐controlled, Phase II clinical trial of deferasirox, which enrolled 166 patients with the three primary diagnostic groups of NTDT and considerable iron burden (Taher *et al*, [2012](#bjh14373-bib-0035){ref-type="ref"}). The current analyses of baseline data from the large THALASSA database (prior to treatment with deferasirox) examined how erythropoietic and iron metabolism markers inter‐relate within NTDT diagnostic subgroups. With the associations between ineffective erythropoiesis, chronic anaemia and gastrointestinal iron absorption that lead to iron loading in patients with NTDT, we hypothesised that LIC would be associated with biomarkers of iron turnover, anaemia and erythroid expansion, particularly in untransfused and unchelated patient subgroups. Baseline markers of iron storage (serum ferritin and LIC) and iron turnover (transferrin saturation \[TfSat\], non‐transferrin‐bound iron \[NTBI\] and labile plasma iron \[LPI\]) were examined, as well as markers of erythroid expansion (soluble transferrin receptor \[sTfR\], GDF‐15 and nucleated red blood cells \[NRBCs\]). Markers of anaemia (Hb and EPO) were compared between the NTDT subgroups and related to the iron metabolism markers. Plasma hepcidin was measured in all subgroups at baseline and related to markers of iron storage, iron turnover, erythroid expansion, anaemia and hypoxia. The effects of previous management strategies (splenectomy and prior transfusion therapy) on these markers were also examined.

Methods {#bjh14373-sec-0002}
=======

Study design {#bjh14373-sec-0003}
------------

THALASSA was a multinational, prospective, randomised, double‐blind, placebo‐controlled, Phase II study (ClinicalTrials.gov number NCT00873041) for which the study design and inclusion/exclusion criteria have been described previously (Taher *et al*, [2012](#bjh14373-bib-0035){ref-type="ref"}). Briefly, male or female patients aged ≥10 years with NTDT, iron overload (LIC ≥5 mg Fe/g dry weight \[dw\] by R2 magnetic resonance imaging \[MRI\]) and serum ferritin \>300 μg/l who received no transfusions within 6 months or chelation therapy within 1 month before study entry were included. Patients with previous exposure to deferasirox were excluded, although patients may have received deferoxamine (DFO), deferiprone or a combination of the two. Additional exclusion criteria included Hb S variants of thalassaemia syndromes, active hepatitis B or hepatitis C, cirrhosis, alanine aminotransferase levels \>5 × the upper limit of normal (ULN), serum creatinine \>ULN or creatinine clearance ≤60 ml/min on two consecutive measurements, or significant proteinuria (urine protein/urine creatinine ratio \>1·0 mg/mg) on two consecutive measurements. Patients (or parents/guardians) provided written, informed consent prior to enrolment. No patients received any transfusions within 6 months or chelation therapy within 1 month prior to enrolment. The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki and was approved by the local ethics committees of the study sites.

Assessments {#bjh14373-sec-0004}
-----------

The THALASSA trial included an initial screening period of 4 weeks, composed of two visits at least 14 days apart. During screening, LIC was measured at one visit using a validated R2 MRI technique (FerriScan^®^, Resonance Health, Claremont, Australia) and adopted as the baseline measurement (St Pierre *et al*, [2005](#bjh14373-bib-0030){ref-type="ref"}). Serum ferritin levels were measured at both screening visits, and baseline levels were calculated from the mean of the two measurements (with a minimum time lag of 14 days between the two assessments). NRBCs and plasma Hb levels were also measured at both screening visits. TfSat, sTfR, NTBI, LPI, EPO, hepcidin and GDF‐15 were measured at baseline (pre‐dose). TfSat was directly measured using the urea gel method and NTBI was detected using high‐performance liquid chromatography at University College London, London, UK, as described elsewhere (Lal *et al*, [2013](#bjh14373-bib-0014){ref-type="ref"}; Porter *et al*, [2014](#bjh14373-bib-0026){ref-type="ref"}). The LPI assay (FeROS^™^ LPI, Aferrix Ltd., Tel Aviv, Israel) was performed using methods described previously (Esposito *et al*, [2003](#bjh14373-bib-0005){ref-type="ref"}). Plasma hepcidin was determined at King\'s College London, London, UK (Bansal *et al*, [2009](#bjh14373-bib-0001){ref-type="ref"}). All remaining blood chemistry samples were analysed at a central laboratory.

Statistical methods {#bjh14373-sec-0005}
-------------------

Demographic and other baseline data (including disease characteristics) are summarised descriptively. All analyses were performed for all patients and by diagnostic subgroup: β TI, Hb E/β thalassaemia and Hb H syndromes. Correlations were assessed by Pearson\'s correlation coefficients and scatter plots, with simple linear regression models; GDF‐15 and EPO were analysed as log values for these analyses. Nominal *P*‐values are provided and were considered significant when \<0·05.

Results {#bjh14373-sec-0006}
=======

Baseline demographics and patient characteristics {#bjh14373-sec-0007}
-------------------------------------------------

In total, 166 patients were enrolled (Table [1](#bjh14373-tbl-0001){ref-type="table-wrap"}). Most patients had β TI (*n* = 95, 57·2%) or Hb E/β thalassaemia (*n* = 49, 29·5%), while the remaining 13·3% (*n* = 22) had predominantly Hb H syndromes (Hb H disease \[*n* = 8\], Hb H‐CS \[*n* = 6\], genotype not determined \[*n* = 6\], HbH‐CS and heterozygous HbE \[CSEA\] Bart\'s \[*n* = 1\] or Hb Agrino \[*n* = 1\]). Age was similar across all groups. Splenectomy, previous transfusions and prior chelation therapy were least frequent in patients with Hb H syndromes and most likely in β TI patients (Table [1](#bjh14373-tbl-0001){ref-type="table-wrap"}). Splenectomy was less frequent in patients with Hb E/β thalassaemia than in patients with β TI. Previous chelation therapy was most frequent in patients with β TI (40%) and least frequent in patients with Hb H syndromes (5%). The proportion of patients who received sporadic or more frequent transfusions and the median number of transfusions were similar across diagnostic subgroups.

###### 

Baseline demographics and patient characteristics by underlying disease

  Characteristic                                                                          All patients (*n* = 166)   β TI (*n* = 95)   Hb E/β thalassaemia (*n* = 49)   Hb H syndromes (*n* = 22)
  --------------------------------------------------------------------------------------- -------------------------- ----------------- -------------------------------- ---------------------------
  Age at screening, years                                                                                                                                               
  Mean ± SD                                                                               32·1 ± 12·0                33·0 ± 11·7       27·7 ± 11·1                      37·7 ± 12·4
  Median (range)                                                                          31·5 (10--69)              33·0 (11--69)     27·0 (10--52)                    35·5 (18--60)
  Splenectomy, *n* (%)                                                                    88 (53·0)                  67 (70·5)         18 (36·7)                        3 (13·6)
  Transfused previously (sporadic), *n* (%)                                               145 (87·3)                 80 (84·2)         47 (95·9)                        18 (81·8)
  Median (range) number of previous transfusions[a](#bjh14373-note-0003){ref-type="fn"}   8 (1--75)                  10 (1--75)        6 (1--47)                        6 (1--43)
  Patients with 1--\<10, *n* (%)                                                          76 (45·8)                  38 (40·0)         29 (59·2)                        9 (40·9)
  Patients with ≥10,[b](#bjh14373-note-0004){ref-type="fn"} *n* (%)                       65 (39·2)                  39 (41·1)         18 (36·7)                        8 (36·4)
  Previous chelation therapy,[c](#bjh14373-note-0005){ref-type="fn"} *n* (%)              44 (26·5)                  37 (38·9)         6 (12·2)                         1 (4·5)

β TI, β thalassaemia intermedia; Hb, haemoglobin; SD, standard deviation.

The proportion of patients who received sporadic or more frequent transfusions was similar across diagnostic subgroups.

Patients did not receive any transfusion in the 6 months prior to study entry and data were missing in four patients.

Data were missing in four patients.

Patients did not receive any chelation therapy within 1 month prior to study entry and patients with previous exposure to deferasirox were excluded.
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Anaemia and erythropoietic biomarkers {#bjh14373-sec-0008}
-------------------------------------

### Baseline levels {#bjh14373-sec-0009}

All patient subgroups were anaemic with elevated EPO levels (Table [2](#bjh14373-tbl-0002){ref-type="table-wrap"}). However, Hb levels were notably higher and EPO levels lower in patients with Hb H syndromes compared with other diagnostic subgroups, while Hb levels were lowest in patients with Hb E/β thalassaemia. Markers associated with ineffective erythropoiesis (sTfR, GDF‐15 and NRBC) were also lowest in patients with Hb H syndromes (Table [2](#bjh14373-tbl-0002){ref-type="table-wrap"}).

###### 

Baseline anaemia, erythroid expansion, iron storage and iron turnover biomarkers in all patients and by diagnostic subgroup

  Parameter, median (range)                              All patients (*n* = 166)   β TI (*n* = 95)         Hb E/β thalassaemia (*n* = 49)   Hb H syndromes (*n* = 22)   Laboratory normal ranges
  ------------------------------------------------------ -------------------------- ----------------------- -------------------------------- --------------------------- -----------------------------------------------------
  Hb, g/l                                                81·0 (47·0--140·0)         84·0 (47·0--140·0)      72·0 (50·0--93·0)                91·0 (55·0--106·0)          113--175
  EPO, u/l                                               101·0 (18·3--3405·0)       108·0 (18·3--3405·0)    115·0 (19·1--649·0)              57·0 (26·1--403·0)          3·7--31·5
  NRBC,/100 WBC                                          45·3 (0·0--827·5)          128·5 (0·0--827·5)      18·0 (0·0--631·0)                1·00 (0·0--17·0)            0
  sTfR, mg/l                                             28·7 (8·3--64·3)           27·9 (8·3--56·5)        30·5 (17·4--51·3)                24·9 (11·6--64·3)           1·9--5·0
  GDF‐15, ng/l                                           9144 (689--53 730)         10,864 (1075--53 730)   9114 (1748--31 667)              2081 (689--6515)            337--1060
  Serum ferritin, μg/l                                   992 (304--6419)            956 (304--3176)         1050 (393--6419)                 1084 (330--3365)            15--400
  LIC, mg Fe/g dw                                        12·1 (2·6--49·1)           11·7 (2·6--49·1)        14·7 (5·0--42·1)                 11·3 (6·2--34·6)            \<1·8[\[Link\]](#bjh14373-note-0008){ref-type="fn"}
  TfSat, %                                               88·0 (24·0--100·0)         88·5 (24·0--100·0)      88·0 (32·0--97·0)                77·0 (42·1--98·3)           20--55
  NTBI, μmol/l[\*](#bjh14373-note-0008){ref-type="fn"}   2·2 (--3·2--8·5)           1·8 (--3·2--8·5)        2·6 (--1·7--5·5)                 1·8 (--2·7--7·5)            0·3--1·5
  LPI, LPI units                                         0·0 (0·0--2·9)             0·0 (0·0--2·9)          0·0 (0·0--1·7)                   0·0 (0·0--2·4)              0--0·4
  Hepcidin, nmol/l                                       4·4 (0·1--51·0)            3·8 (0·1--51·0)         5·6 (0·8--38·7)                  5·0 (1·2--15·7)             2·0--7·5
  Hepcidin/serum ferritin ratio·1000                     5·0 (0·0--50·0)            4·0 (0·0--40·0)         6·0 (0·0--50·0)                  5·0 (0·0--50·0)             23·2[\[Link\]](#bjh14373-note-0008){ref-type="fn"}

β TI, β thalassaemia intermedia; dw, dry weight; EPO, erythropoietin; GDF‐15, growth differentiation factor 15; Hb, haemoglobin; LIC, liver iron concentration; LPI, labile plasma iron; NRBC, nucleated red blood cell; NTBI, non‐transferrin‐bound iron; sTfR, soluble transferrin receptor; TfSat, transferrin saturation; WBC, white blood cells.

All patient subgroups were anaemic, with elevated iron metabolism parameters above the normal ranges, although LPI was generally not detected Note: Baseline is defined as the average of all values measured before or on the day of the first dose of study medication.

\*Negative values can be interpreted as NTBI being absent from the sample; ^1^(St Pierre *et al*, [2005](#bjh14373-bib-0030){ref-type="ref"}); ^2^(Porter *et al*, [2014](#bjh14373-bib-0026){ref-type="ref"}).
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### Relationships between anaemia, erythropoiesis and iron metabolism {#bjh14373-sec-0010}

There was a negative correlation between Hb and EPO in the overall population as expected (*r* = −0·35; *P *\<* *0·0001; Table SII). The EPO‐to‐Hb relationship was stronger in patients with Hb H syndromes (*r *= −0·76; *P *\<* *0·0001) than in patients with Hb E/β thalassaemia (*r* = −0·42; *P *=* *0·0028) and β TI (*r* = −0·32; *P *=* *0·0022). Across all patients, sTfR was negatively related to Hb levels (*r* = −0·46; *P *\<* *0·0001; Fig [1](#bjh14373-fig-0001){ref-type="fig"}A) and positively correlated with EPO (*r* = 0·47; *P *\<* *0·0001; Fig [1](#bjh14373-fig-0001){ref-type="fig"}B). This was also evident by diagnostic subgroup (Tables SIII, SIV and SV). A negative relationship was present between Hb and NRBCs (*r* = −0·46, *P *=* *0·0016) and between Hb and sTfR (*r *= −0·42, *P *=* *0·0024) in patients with Hb E/β thalassaemia (Table SIV), consistent with more severe anaemias driving increased erythropoiesis; no relationship between Hb and GDF‐15 was apparent.

![Correlations between sTfR and (A) Hb (B) NTBI (C) GDF‐15 and (D) NRBCs. Evaluable biomarkers of erythroid expansion generally correlated with each other. The strong negative correlation of Hb levels with sTfR supports the concept that sTfR levels reflect erythroid mass, which increases with greater anaemia. GDF‐15, growth differentiation factor‐15; Hb, haemoglobin; NRBC, nucleated red blood cells; NTBI, non‐transferin‐bound iron; sTfR, soluble transferrin receptor.](BJH-176-288-g001){#bjh14373-fig-0001}

Iron overload and iron metabolism biomarkers {#bjh14373-sec-0011}
--------------------------------------------

### Baseline levels {#bjh14373-sec-0012}

Across all diagnostic subgroups, markers of iron storage (LIC and serum ferritin) were raised but similar. Iron turnover biomarkers (TfSat and NTBI) were elevated above normal ranges with lower TfSat and NTBI in patients with Hb H syndromes (Table [2](#bjh14373-tbl-0002){ref-type="table-wrap"}). Overall, median TfSat was 88% (range 24·0% to 100·0%); 34/158 (21·5%) patients with TfSat measured at baseline had 100% TfSat, which contrasts with transfusion‐dependent (TDT) patients, in whom TfSat is typically 100%. LPI was generally not detectable across all subgroups, but reached levels above normal (\>0·4 units) in 22 patients overall (β TI, *n* = 16; Hb E/β thalassaemia, *n* = 5; Hb H syndromes, *n* = 1). Hepcidin levels were generally within the normal range, although slightly lower in β TI patients than in the other two patient subgroups (Table [2](#bjh14373-tbl-0002){ref-type="table-wrap"}). The hepcidin/serum ferritin ratio was similar for all diagnostic subgroups (Table [2](#bjh14373-tbl-0002){ref-type="table-wrap"}) and notably less than that described elsewhere in TDT and sickle‐cell disease (SCD) patients, using similar methodology for plasma hepcidin measurement (Porter *et al*, [2014](#bjh14373-bib-0026){ref-type="ref"}). This is consistent with hepcidin suppression relative to iron overload in NTDT patients across all subgroups. Hepcidin levels were highest in patients with a history of \>20 blood transfusions, despite serum ferritin and LIC being no higher in this group.

### Relationships between iron storage, iron turnover and hepcidin {#bjh14373-sec-0013}

Strong correlations were seen between LIC and serum ferritin overall (*r* = 0·64; *P *\<* *0·0001) and in all diagnostic subgroups (Tables SIII, SIV and SV), with similar slopes (data not shown). TfSat correlated with NTBI (*r* = 0·84; *P *\<* *0·0001), LIC (*r* = 0·37; *P *\<* *0·0001), serum ferritin (*r* = 0·35; *P *\<* *0·0001) and LPI (*r* = 0·30; *P *=* *0·0002; Fig [2](#bjh14373-fig-0002){ref-type="fig"}). The relationship between TfSat and NTBI was continuous (Fig [2](#bjh14373-fig-0002){ref-type="fig"}C), whereas the relationship between TfSat and LPI appeared binary or possibly hyperbolic, with LPI absent (except in four cases) when TfSat was \<98% (Fig [2](#bjh14373-fig-0002){ref-type="fig"}D). This may explain the apparent absence of LPI across diagnostic subgroups, as TfSat was typically \<100% (Table [2](#bjh14373-tbl-0002){ref-type="table-wrap"}). NTBI also correlated with LIC (*r* = 0·35; *P *\<* *0·0001; Fig [3](#bjh14373-fig-0003){ref-type="fig"}A) and serum ferritin (*r* = 0·39; *P *\<* *0·0001; Fig [3](#bjh14373-fig-0003){ref-type="fig"}B). The relationships between iron storage and iron turnover parameters were generally stronger in patients with Hb E/β thalassaemia and Hb H syndromes than in β TI patients (Tables SIII, SIV and SV). Moderate‐to‐strong correlations between hepcidin and both TfSat and NTBI were identified (*r* = −0·33; *P *\<* *0·0001 and *r* = −0·24; *P *=* *0·0029, respectively; Fig [4](#bjh14373-fig-0004){ref-type="fig"}A and [4](#bjh14373-fig-0004){ref-type="fig"}B). There was no correlation between hepcidin and markers of iron storage (Table SII). This was consistent across underlying diseases (Tables SIII, SIV and SV).

![Correlations between TfSat and markers of iron storage: (A) LIC and (B) serum ferritin; and markers of iron turnover: (C) NTBI and (D) LPI. The relationship between TfSat and NTBI was continuous, whereas the relationship between TfSat and LPI appeared binary. β TI, β thalassaemia intermedia; dw, dry weight; Hb, haemoglobin; LIC, liver iron concentration; LPI, labile plasma iron; NTBI, non‐transferrin‐bound iron; TfSat, transferrin saturation.](BJH-176-288-g002){#bjh14373-fig-0002}

![Correlations between NTBI and markers of iron storage: (A) LIC and (B) serum ferritin. Strong correlations were noted between NTBI as a marker of iron turnover and LIC and serum ferritin, markers of iron storage. dw, dry weight; LIC, liver iron concentration; NTBI, non‐transferrin‐bound iron.](BJH-176-288-g003){#bjh14373-fig-0003}

![Correlations between hepcidin and markers of iron turnover: (A) TfSat and (B) NTBI. Hepcidin correlated with markers of iron turnover, but not markers of iron storage. β TI, β thalassaemia intermedia; dw, dry weight; NTBI, non‐transferrin‐bound iron; TfSat, transferrin saturation.](BJH-176-288-g004){#bjh14373-fig-0004}

### Relationships between erythroid expansion, iron metabolism and hepcidin {#bjh14373-sec-0014}

Evaluable biomarkers of erythroid expansion generally correlated with each other. Overall, there were strong, positive associations between sTfR and GDF‐15 (Fig [1](#bjh14373-fig-0001){ref-type="fig"}C) and between sTfR and NRBCs (Fig [1](#bjh14373-fig-0001){ref-type="fig"}D). Moderate, yet significant, correlations between markers of erythron expansion (sTfR, NRBC and GDF‐15) and iron turnover were also identified (Table SII): NTBI and sTfR (*r* = 0·20; *P *=* *0·013); NTBI and NRBC (*r* = 0·23; *P *=* *0·0041); TfSat and GDF‐15 (*r* = 0·17; *P *=* *0·0402); and TfSat and NRBC (*r* = 0·26; *P *=* *0·0014). These correlations were generally stronger in patients with Hb E/β thalassaemia or Hb H syndromes (Tables SIV and SV). Markers of erythron expansion (sTfR, NRBC and GDF‐15) were not correlated with those of iron storage in patients as a whole, although relationships were identified in patients with Hb H syndromes: between LIC and sTfR (*r* = 0·44; *P *=* *0·04) and between LIC and GDF‐15 (*r* = 0·47; *P *=* *0·027). This may be because most of these patients had not received prior chelation therapy, unlike the other diagnostic subgroups. Hepcidin generally did not correlate with markers of erythroid expansion (GDF‐15 or sTfR; Table SII) except in patients with Hb E/β thalassaemia, where a significant inverse correlation between hepcidin and GDF‐15 was seen (*r* = −0·3; *P *=* *0·0084). A significant inverse relationship between hepcidin and NRBCs was also identified overall (*r* = −0·21; *P *=* *0·0081), as well as in patients with Hb E/β thalassaemia (Table SII).

Effects of previous management: transfusion and splenectomy {#bjh14373-sec-0015}
-----------------------------------------------------------

### Prior blood transfusion {#bjh14373-sec-0016}

The majority of patients received sporadic transfusions prior to enrolment (Table [1](#bjh14373-tbl-0001){ref-type="table-wrap"}), with a median of eight lifetime transfusion episodes, although the number was highly variable (range 1--75; Table [1](#bjh14373-tbl-0001){ref-type="table-wrap"}). A higher proportion of patients with Hb H syndromes received no prior transfusions (22·7% Hb H syndromes vs 18·7% β TI and 4·1% Hb E/β thalassaemia patients). Nearly all Hb E/β thalassaemia patients had previously received transfusion therapy, possibly because patients were more anaemic (median Hb levels 72·0 g/l). Patients with prior transfusions generally had lower Hb levels and higher NRBCs and EPO, indicative of a greater degree of ineffective erythropoiesis, as well as increased iron storage and iron turnover biomarkers (Table [3](#bjh14373-tbl-0003){ref-type="table-wrap"}). LIC and serum ferritin levels were not related to the number of previous transfusions, presumably because of previous chelation therapy. TfSat and sTfR levels progressively increased in patients who received more transfusions. Hepcidin levels were also notably increased in patients who had received \>20 previous transfusions. NTBI was generally absent in patients in the absence of prior transfusions (the majority were β TI patients; Table [1](#bjh14373-tbl-0001){ref-type="table-wrap"}), in contrast to transfused patients.

###### 

Iron and haematological parameters in all patients by number of previous transfusions

  Parameter, median (range)                             Number of previous transfusions                                                 
  ----------------------------------------------------- --------------------------------- ---------------------- ---------------------- ---------------------
  Serum ferritin, μg/l                                  622 (304--1473)                   1054 (374--6419)       1085 (370--3065)       988 (342--3365)
  LIC, mg Fe/g dw                                       7·4 (5·8--28·6)                   13·5 (5·0--42·1)       13·0 (2·6--49·1)       10·7 (5·1--32·2)
  TfSat, %                                              72·0 (26·0--92·0)                 88·0 (32·0--100·0)     89·5 (29·0--98·3)      80·5 (24·0--95·0)
  NTBI, μmol/l[a](#bjh14373-note-0011){ref-type="fn"}   --0·03 (--2·8--4·0)               2·39 (--3·2--8·5)      2·4 (--2·0--7·5)       1·6 (--1·7--5·0)
  LPI, LPI units                                        0·0 (0·0--0·4)                    0·0 (0·0--1·9)         0·0 (0·0--2·9)         0·0 (0·0--0·8)
  Hepcidin, nmol/l                                      4·2 (0·1‒10·3)                    4·3 (0·3‒51·0)         4·2 (0·1‒20·9)         6·9 (0·5‒47·0)
  Hb, g/l                                               95·0 (69·0--140·0)                78·0 (52·0--124·0)     80·0 (47·0--118·0)     76·0 (50·0--100·0)
  EPO, u/l                                              69·0 (31·2--843·0)                101·0 (18·3--3405·0)   101·0 (35·5--1957·0)   142·0 (28·4--644·0)
  NRBC,/100 WBC                                         3·5 (0·0--361·0)                  27·5 (0·0--631·0)      207·0 (0·0--827·5)     11·0 (0·0--420·5)
  sTfR, mg/l                                            24·6 (9·9--41·7)                  27·4 (8·3--64·3)       29·4 (18·0--56·5)      31·7 (22·4--42·1)
  GDF‐15, ng/l                                          9179 (689--20 234)                8599 (748--53 730)     10,053 (890--46 511)   9114 (1089--30 778)

dw, dry weight; EPO, erythropoietin; GDF‐15, growth differentiation factor 15; Hb, haemoglobin; LIC, liver iron concentration; LPI, labile plasma iron; NRBC, nucleated red blood cell; NTBI, non‐transferrin‐bound iron; sTfR, soluble transferrin receptor; TfSat, transferrin saturation; WBC, white blood cells.

TfSat and sTfR levels were progressively increased in patients who received more transfusions and hepcidin levels were notably increased in patients who received \>20 previous transfusions. Note: Data were missing in four patients.

Negative values can be interpreted as NTBI being absent from the sample.

John Wiley & Sons, Ltd

### Prior splenectomy {#bjh14373-sec-0017}

Overall, 53% (*n* = 88) of patients were splenectomised (Table [1](#bjh14373-tbl-0001){ref-type="table-wrap"}). In splenectomised *versus* non‐splenectomised patients, median (range) serum ferritin levels and LIC were slightly elevated \[1116 μg/l (370--6419) vs 834 μg/l (304--3365) and 12·9 mg Fe/g dw (2·6--39·3) vs 11·6 mg Fe/g dw (5·0--49·1), respectively\]. The relationship between LIC and serum ferritin differed in splenectomised patients (*r* = 0·764; *P *\<* *0·0001 \[*n* = 88\]) *versus* non‐splenectomised patients (*r* = 0·552; *P *\<* *0·0001 \[*n* = 77\]), as the serum ferritin increment was greater in relation to LIC in splenectomised patients (Fig [5](#bjh14373-fig-0005){ref-type="fig"}). No differences were noted between LIC and other markers of iron metabolism, TfSat and NTBI (data not shown). However, both NTBI and TfSat were notably higher in splenectomised *versus* non‐splenectomised patients \[2·5 μmol/l (−1·9--8·5) vs 0·6 μmol/l (−3·2--7·5) and 91·0% (43·0--100·0) vs 78·0% (24·0--98·3), respectively; Fig [6](#bjh14373-fig-0006){ref-type="fig"}A, B). Splenectomised patients also had higher median (range) GDF‐15 levels and NRBCs than non‐splenectomised patients (Fig [6](#bjh14373-fig-0006){ref-type="fig"}C, D): 10 300 ng/l (1075--53 730) *versus* 7903 ng/l (689--46 511) and 235·0/100 white blood cells (WBC) (3·5--827·5) vs 4·0/100 WBC (0·0--56·0), respectively. Levels of EPO and Hb were similar: 101·0 u/l (18·3--3405·0) vs 101·0 u/l (19·1--1957·0) and 81·0 g/l (47·0--118·0) vs 81·0 g/l (55·0--140·0), respectively.

![Correlation between serum ferritin and LIC in splenectomised and non‐splenectomised patients. The relationship between LIC and serum ferritin differed in splenectomised patients, as the serum ferritin increment was greater in relation to LIC. dw, dry weight; LIC, liver iron concentration.](BJH-176-288-g005){#bjh14373-fig-0005}

![Median ± IQR baseline levels of (A) NTBI, (B) TfSat, (C) GDF‐15 and (D) NRBCs in splenectomised and non‐splenectomised patients. Splenectomised patients generally had higher levels of NTBI, TfSat, GDF‐15 and NRBCs. GDF‐15, growth differentiation factor 15; IQR, interquartile range; NRBC, nucleated red blood cell; NTBI, non‐transferrin‐bound iron; TfSat, transferrin saturation.](BJH-176-288-g006){#bjh14373-fig-0006}

Discussion {#bjh14373-sec-0018}
==========

To our knowledge, this is the first study to compare a range of biomarkers of iron metabolism and erythropoiesis, including plasma hepcidin, across a range of diagnostic NTDT subgroups. Our findings provide insight into the heterogeneity and similarities across NTDT syndromes, as well as the pathophysiological processes associated with the expanded erythroid and disordered iron metabolism. Patients enrolled in the THALASSA study were not currently receiving regular transfusions or chelation within the past month, but were sufficiently iron overloaded, as defined by LIC and serum ferritin levels, to potentially benefit from iron chelation therapy (Taher *et al*, [2012](#bjh14373-bib-0035){ref-type="ref"}). Even without a history of transfusions, iron overload occurred across the spectrum of NTDT subgroups.

Anaemia and hypoxia {#bjh14373-sec-0019}
-------------------

Increased markers of anaemia, hypoxia, ineffective erythropoiesis and erythroid expansion (sTfR, GDF‐15 and NRBC) were seen across all NTDT subgroups. These markers were distinctly lower in patients with Hb H syndromes and higher in those with β TI. Hb E/β thalassaemia patients were, on average, more anaemic than those with β TI, but EPO levels were similar to β TI patients (Table [2](#bjh14373-tbl-0002){ref-type="table-wrap"}). This is consistent with the right‐shifted oxygen dissociation curve and typically lower Hb F levels in patients with Hb E/β thalassaemia than with β TI (Rees *et al*, [1999](#bjh14373-bib-0028){ref-type="ref"}). The negative correlation between Hb levels and EPO across all patient groups supports the known EPO response to anaemia and hypoxia (Premawardhena *et al*, [2005](#bjh14373-bib-0027){ref-type="ref"}; O\'Donnell *et al*, [2007](#bjh14373-bib-0020){ref-type="ref"}; Taher *et al*, [2011](#bjh14373-bib-0034){ref-type="ref"}). The weaker relationship between EPO and Hb in patients with β TI may also be due to increased variability in the presence of Hb F (Galanello *et al*, [1994](#bjh14373-bib-0009){ref-type="ref"}), which was not measured in this study. The strong negative correlation of Hb levels with sTfR (Fig [1](#bjh14373-fig-0001){ref-type="fig"}A) supports the concept that sTfR levels reflect erythroid mass, which increases with greater anaemia. Indeed, sTfR levels have been linked with the incidence of extramedullary erythropoiesis in β TI patients (Ricchi *et al*, [2012](#bjh14373-bib-0029){ref-type="ref"}). It is notable that patients with the most previous transfusion episodes (\>20) had the lowest Hb values and the highest EPO and sTfR levels, indicative of a group of patients with the greatest demand on the erythron when not regularly transfused.

TfSat, NTBI and LPI {#bjh14373-sec-0020}
-------------------

Across NTDT subgroups, raised TfSat and NTBI were associated with increased blood transfusion history, splenectomy, increased sTfR, increased NRBCs and lower plasma hepcidin. The strong correlation between TfSat and NTBI, observed for all NTDT subgroups, is consistent with the relationship previously identified in haemochromatosis and thalassaemia major (Loreal *et al*, [2000](#bjh14373-bib-0015){ref-type="ref"}; Walter *et al*, [2008](#bjh14373-bib-0041){ref-type="ref"}). In this study, NTBI was predominantly evident in patients when TfSat exceeded approximately 80%. TfSat is a relatively simple and inexpensive marker and we would recommend its use when NTBI is not routinely available. Prior use of transfusions appeared to be a key factor in the generation of NTBI and TfSat. NTBI was absent in patients without previous transfusions despite median LIC values \>7 mg Fe/g dw (Table [3](#bjh14373-tbl-0003){ref-type="table-wrap"}). This observation suggests that increased macrophage iron may be a key factor in the generation of NTBI because patients overloaded from gastrointestinal iron absorption alone have predominantly periportal hepatocellular iron, whereas transfusion therapy initially loads iron to the macrophage compartment (Origa *et al*, [2007](#bjh14373-bib-0021){ref-type="ref"}). Rapid egress of iron is the key route to transferrin binding and, potentially, NTBI generation (Porter *et al*, [2014](#bjh14373-bib-0026){ref-type="ref"}). By contrast, LPI levels showed no obvious relationship to blood transfusion. LPI was not detected in the majority of patients (i.e. levels below the ULN of 0·4 units), whereas other markers of iron storage and iron turnover were elevated. Raised LPI levels were mainly confined to those patients with 100% TfSat \[*n* = 34 (21·5%); Fig [2](#bjh14373-fig-0002){ref-type="fig"}D\], which explains why, on average, LPI was generally not raised. These findings suggest that LPI is unlikely to be a useful marker of small changes in iron overload in NTDT patients. The binary or hyperbolic relationship of LPI to TfSat (Fig [2](#bjh14373-fig-0002){ref-type="fig"}D) also contrasts with the continuum seen between NTBI and TfSat (Fig [2](#bjh14373-fig-0002){ref-type="fig"}C), suggesting that NTBI and LPI identify different iron species in NTDT. As NTDT patients are typically at lower risk of extra‐hepatic iron damage than TDT patients, where LPI is usually raised, this may be consistent with the notion that LPI is a fraction of NTBI that is more likely to distribute extra‐hepatically (Cabantchik *et al*, [2005](#bjh14373-bib-0003){ref-type="ref"}).

Relevance of splenectomy {#bjh14373-sec-0021}
------------------------

Higher NTBI values in splenectomised than in non‐splenectomised patients have been previously reported for patients with β TI (Taher *et al*, [2009b](#bjh14373-bib-0033){ref-type="ref"}). This could represent a more severe subset of patients who required splenectomy. Further studies of NTBI (and LPI) in patients pre‐ and post‐splenectomy would address this issue. Another explanation, however, is that splenectomy diverts erythrophagocytosis away from the spleen, where any NTBI generated would have been cleared efficiently as a first pass by hepatocytes (Brissot *et al*, [1985](#bjh14373-bib-0002){ref-type="ref"}). When erythrophagocytosis is diverted to the marrow, NTBI clearance by the liver will occur only after systemic circulation and, hence, with higher NTBI levels and greater extra‐hepatic iron uptake.

Erythrocytic expansion and iron overload {#bjh14373-sec-0022}
----------------------------------------

The relationship between markers of iron overload and those of erythron expansion is of mechanistic interest as bone‐marrow‐derived factors, such as erythroferrone (Kautz *et al*, [2014](#bjh14373-bib-0012){ref-type="ref"}), are thought to increase iron absorption through suppression of hepcidin. Unfortunately, many patients with β TI and Hb E/β thalassaemia had received previous transfusion and chelation therapy, thus obscuring such relationships. Only in patients with Hb H syndromes, where transfusion and chelation therapy are rarely used, could relationships between erythron expansion and iron overload be reliably explored. Patients with Hb H syndromes received less chelation (only one patient) and had lower splenectomy rates than other NTDT patient subgroups, even though serum ferritin levels and LIC were increased to a similar degree. Therefore, the correlations between markers of iron overload and erythroid expansion in patients with Hb H syndromes are of particular interest and support a relationship between ineffective erythropoiesis and increased iron absorption across NTDT subgroups. These findings should also be considered in the light of newly discovered markers of ineffective erythropoiesis \[e.g. GDF‐11 (Dussiot *et al*, [2014](#bjh14373-bib-0004){ref-type="ref"}) and erythroferrone (Kautz *et al*, [2014](#bjh14373-bib-0012){ref-type="ref"})\], which were reported after the completion of the THALASSA trial (Taher *et al*, [2012](#bjh14373-bib-0035){ref-type="ref"}). Analyses of these biomarkers may provide a more complete interpretation of the relationships between erythrocytic expansion and iron overload in patients with NTDT.

Plasma hepcidin {#bjh14373-sec-0023}
---------------

Hepcidin is a key molecule in the regulation of iron metabolism. Generally, plasma levels are thought to be increased by iron overload and decreased by erythron expansion. Our findings support a general relationship between hepcidin and Hb. Hepcidin levels were not elevated above normal reference ranges across all NTDT subgroups, despite the presence of iron overload. This is consistent with inhibitory effects from expanded bone marrow (Tanno *et al*, [2007](#bjh14373-bib-0038){ref-type="ref"}; Kautz *et al*, [2014](#bjh14373-bib-0012){ref-type="ref"}) outweighing the stimulatory effects of iron overload. It is of interest that hepcidin levels were least suppressed in patients receiving \>20 previous transfusion episodes (Table [3](#bjh14373-tbl-0003){ref-type="table-wrap"}). Another way of examining these competing effects is with the hepcidin/serum ferritin ratio (Pasricha *et al*, [2013](#bjh14373-bib-0023){ref-type="ref"}). Recently, this ratio (hepcidin \*1000/serum ferritin) was found to be higher in controls (ratio = 23·2) than in patients with thalassaemia major or SCD (Porter *et al*, [2014](#bjh14373-bib-0026){ref-type="ref"}). In the NTDT patients from the THALASSA trial, the average ratio was approximately 4·4 across all NTDT subgroups (4·0 in β TI; 6·0 in Hb E/β thalassaemia; 5·0 in Hb H syndromes). This ratio is consistent with moderate generalised hepcidin suppression when corrected for iron overload, presumably as a consequence of erythroid expansion. In this cross‐sectional analysis, we also showed that plasma hepcidin in patients with NTDT was more closely related to markers of iron turnover (TfSat and NTBI) than to iron storage (serum ferritin and LIC). Therefore, single measurements of plasma hepcidin are unlikely to be a useful marker of iron overload in NTDT patients.

LIC and serum ferritin {#bjh14373-sec-0024}
----------------------

The importance of the relationship between the two markers of iron storage, LIC and serum ferritin, lies mainly in the practical management of iron overload in NTDT patients. Increased LIC and serum ferritin levels in NTDT patients are associated with increased morbidities, including vascular, endocrine and bone diseases (Musallam *et al*, [2011](#bjh14373-bib-0016){ref-type="ref"}, [2013](#bjh14373-bib-0018){ref-type="ref"}, [2014](#bjh14373-bib-0019){ref-type="ref"}). Serum ferritin underestimates body iron stores in NTDT patients in comparison with patients with TDT (Pakbaz *et al*, [2007](#bjh14373-bib-0022){ref-type="ref"}; Taher *et al*, [2008](#bjh14373-bib-0031){ref-type="ref"}; Lal *et al*, [2011](#bjh14373-bib-0013){ref-type="ref"}). However, clinically relevant serum ferritin thresholds have been identified (Musallam *et al*, [2014](#bjh14373-bib-0019){ref-type="ref"}; Taher *et al*, [2015](#bjh14373-bib-0036){ref-type="ref"}), providing a convenient and inexpensive method of assessing iron overload and tailoring iron chelation therapy when there is restricted access to MRI technology. In the present study, the relationship between LIC and serum ferritin was consistent across all NTDT subgroups. However, the relationship between these two parameters differed between splenectomised and non‐splenectomised patients as serum ferritin levels were increased relative to LIC in splenectomised patients. A mechanistic interpretation requires consideration. The reported lower serum ferritin levels, relative to LIC, in NTDT *versus* TDT patients is probably secondary to early iron deposition in periportal hepatocytes rather than macrophages (Origa *et al*, [2007](#bjh14373-bib-0021){ref-type="ref"}). As serum ferritin at values \<3000 μg/l are mainly derived from macrophages (Worwood *et al*, [1979](#bjh14373-bib-0043){ref-type="ref"}), the hepatocellular accumulations are relatively 'invisible' to the assay for serum ferritin. It is likely that splenectomised patients received more transfusions prior to splenectomy than non‐splenectomised patients, thereby leading to greater iron in the macrophage system and, hence, higher serum ferritin levels relative to LIC. Despite these caveats, serum ferritin levels show the closest relationship to LIC of any of the biomarkers examined. Indeed, the other biomarkers, while being of mechanistic interest, do not correlate with LIC closely enough to justify clinical decisions about chelation therapy to be made on the basis of their levels.

Conclusions {#bjh14373-sec-0025}
===========

These analyses add insight into the complex interactions between anaemia, ineffective erythropoiesis and iron metabolism, as well as previous clinical management across the clinical spectrum of NTDT patients. Importantly, we have observed increased markers of iron overload across all underlying diagnostic syndromes, confirming significant iron burden in NTDT patients who may, therefore, benefit from optimised iron chelation therapy. A possible relationship of iron overload to the degree of erythroid expansion was seen in patients with Hb H syndromes but was obscured in other subgroups, most likely due to prior blood transfusions and chelation therapy. These Hb H patients were predominantly untransfused and we suggest that in such patients, biomarkers of erythron expansion could, in principle, be predictive of those patients at most risk of developing iron overload. Future studies should aim to validate these relationships in larger patient groups who have not received transfusion or chelation therapy. Our evidence suggests that NTDT patients are at a low risk of NTBI‐ or LPI‐mediated extra‐hepatic damage unless blood transfusions exceed 20 episodes and transferrin is 100% saturated. Therefore, the history of transfusional iron intake, as well as markers or iron overload, should be considered when assessing patients for iron chelation therapy. The findings with hepcidin are of mechanistic interest, particularly the inverse relationship between hepcidin, TfSat, NTBI and LPI, suggesting that high hepcidin levels may limit TfSat, NTBI and LPI levels in NTDT patients and, hence, the extra‐hepatic distribution of iron. However, our findings suggest that hepcidin measurement would not add significantly to the routine management of NTDT patients. The study patients, while representing a wide diagnostic spectrum, may not be fully representative of the full range of NTDT syndromes in the 'real world,' because less iron‐overloaded patients were excluded from this study. Other parameters would be of interest for future studies, such as erythroferrone, a newly described erythroid regulatory hormone of hepcidin. However, this study is the most comprehensive examination of factors associated with iron overload across the NTDT spectrum.
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